Blog
RSS FeedPosted by Michael Wonder on 23 Mar 2016
Action receives approval for Uptravi (selexipag) for the treatment of pulmonary arterial hypertension in Australia and New Zealand
22 March 2016 - Actelion announced today that the Therapeutic Goods Administration (TGA) of Australia and the New Zealand Medicines and ...
Posted by Michael Wonder on 08 Mar 2016
Specialized Therapeutics grants sublicense for anti-emetic products to Mundipharma
7 March 2016 - Under the terms of the arrangement, Specialized Therapeutics grants Mundipharma exclusive marketing, promotion, distribution and sales rights ...